KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bausch Health Companies (BHC) Change in Receivables (2016 - 2025)

Bausch Health Companies (BHC) has disclosed Change in Receivables for 17 consecutive years, with -$65.0 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 162.5% to -$65.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $134.0 million through Dec 2025, down 37.96% year-over-year, with the annual reading at $134.0 million for FY2025, 37.96% down from the prior year.
  • Change in Receivables hit -$65.0 million in Q4 2025 for Bausch Health Companies, down from $218.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $231.0 million in Q3 2023 to a low of -$197.0 million in Q1 2022.
  • Historically, Change in Receivables has averaged $41.6 million across 5 years, with a median of $58.0 million in 2023.
  • Biggest YoY gain for Change in Receivables was 1047.83% in 2025; the steepest drop was 274.6% in 2025.
  • Year by year, Change in Receivables stood at $52.0 million in 2021, then plummeted by 40.38% to $31.0 million in 2022, then plummeted by 38.71% to $19.0 million in 2023, then soared by 447.37% to $104.0 million in 2024, then crashed by 162.5% to -$65.0 million in 2025.
  • Business Quant data shows Change in Receivables for BHC at -$65.0 million in Q4 2025, $218.0 million in Q3 2025, and $91.0 million in Q2 2025.